Showing 4061-4070 of 9158 results for "".
- Pediatric AD: Tapinarof Cream 1% Delivers Clear Skin and Reduced Burdenhttps://practicaldermatology.com/news/pediatric-ad-tapinarof-cream-1-delivers-clear-skin-and-reduced-burden/2484254/In the pivotal ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA, Organon) showed consistent and statistically significant efficacy across all pediatric age groups in children with atopic dermatitis (AD), with benefits extending to sleep and family impact o
- Tapinarof Sustains AD Remission for 75+ Days Post-Treatmenthttps://practicaldermatology.com/news/tapinarof-sustains-ad-remission-for-75-days-post-treatment/2484253/New long-term data from the ADORING 3 trial show that tapinarof cream 1% (VTAMA, Organon), a non-steroidal topical aryl hydrocarbon receptor agonist, can sustain low disease activity and pruritus in patients with atopic dermatitis (AD), including children as young
- Topical Caffeine May Provide Hair Growth Benefit for Alopecia: Studyhttps://practicaldermatology.com/news/topical-caffeine-may-provide-hair-growth-benefit-for-alopecia-study/2484243/Topical caffeine may be a promising adjunct treatment for hair loss, according to a systematic review published in the Journal of Drugs in Dermatology. The analysis assessed original studies investigating caffeine’s effects on hair growth across multiple fo
- Study IDs Additional Risk Allele in Allopurinol-Induced Cutaneous Reactions in US Patientshttps://practicaldermatology.com/news/study-ids-additional-risk-allele-in-allopurinol-induced-cutaneous-reactions-in-us-patients/2484235/A recently published genetic association study has identified HLA-A34:02 as an independent allele significantly associated with severe cutaneous adverse reactions (SCARs) to allopurinol in a US-based cohort. Researchers from
- TrUE-AD4: Opzelura Shows Rapid, Significant Efficacy in Moderate ADhttps://practicaldermatology.com/news/true-ad4-opzelura-shows-rapid-significant-efficacy-in-moderate-ad/2484225/New data from Incyte’s phase 3b TRuE-AD4 trial show that Opzelura® (ruxolitinib cream 1.5%) improved clinical symptoms of moderate atopic dermatitis (AD) in adults with limited response or intolerance to standard thearpy. The
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- Combination of Clascoterone 1% and Adapalene 0.3% Shows Promise for Acnehttps://practicaldermatology.com/news/combination-of-clascoterone-1-and-adapalene-03-shows-promise-for-acne/2484118/Combination therapy with clascoterone cream 1% and adapalene gel 0.3% significantly improves acne severity and quality of life, while maintaining excellent tolerability in patients with moderate-to-severe acne vulgaris, according to a 16-week pilot study presented
- 487-GEP Test Identifies Optimal Systemic Therapy for ADhttps://practicaldermatology.com/news/487-gep-test-identifies-optimal-systemic-therapy-for-ad/2484115/A 487-gene expression profile (487-GEP) test may help personalize systemic therapy selection for patients with atopic dermatitis (AD), according to results from a prospective, multicenter trial presented by Dr. Jonathan Silverberg et al at the 2025 Fall Clinical De
- Upadacitinib Demonstrates Rapid Improvement in AD Patients With Prurigo Noduleshttps://practicaldermatology.com/news/upadacitinib-demonstrates-rapid-improvement-in-ad-patients-with-prurigo-nodules/2484113/A new interim analysis from the ADMIRE study, presented at the 2025 Fall Clinical Dermatology Conference, reported that upadacitinib yields rapid and sustained improvements in patients with moderate-to-severe atopic dermatitis (AD) complicated by prurigo nodules, o
- Dr. Darrell Rigel Highlights Advances in Skin Cancer Carehttps://practicaldermatology.com/news/dr-darrell-rigel-highlights-advances-in-skin-cancer-care/2484095/Darrell S. Rigel, MD, MS, provided a comprehensive update on the rapidly evolving landscape of skin cancer diagnosis, treatment, and prognostication at the 2025 Fall Clinical Dermatology Conference. From novel genetic assays to refinements in field therapy and systemic strategies, Dr. Rigel’s tal